NSPR logo

INSPIREMD INC

NSPRNASDAQ
πŸ† #4607 by market capUS Equity
$0.45β–Ό $0.01 (βˆ’1.55%)
Pre-market Β· at close
πŸ””
Track NSPR
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 1.6%
7dβ–Ό 1.1%
14dβ–Ό 10.1%
30dβ–Ό 34.9%
ytdβ–Ό 74.7%
1yβ–Ό 80.1%
🏦Market Cap
$21M
Small Cap
πŸ“ˆRevenue Growth (YoY)
28.1%
High Growth
πŸ“ŠGross Margin
18.1%
Thin
πŸ’΅FCF Margin
-391.7%
Thin
βš–οΈP/S Ratio
2.0x
Cheap
Otter Score
β€”
Insufficient data

Trading Snapshot

Day Range
$0.45 – $0.47
52-Week Range
$0.43 – $2.41
Volume (shares)
14,704
Avg Volume (shares)
β€”
Shares Outstanding
46.5M
Next Earnings
β€”

Fundamentals Snapshot

Annual Revenue
$9M
Last Q Revenue
$2M
P/E Ratio
-0.9
P/S Ratio
2.0x
EPS (TTM)
$-0.52
Dividend Yield
0.00%
Dilution (1yr)
+50.3%
NSPR logo

INSPIREMD INC

NSPR
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$9Mβ–² +28.1% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
29.5%β–² +37.3% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$49Mβ–² +46.6% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$37Mβ–² +58.0% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
73.5Mβ–² +50.3% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$6Mβ–Ό βˆ’$11M YoY
StockOtter Β· stockotter.space

About INSPIREMD INC

InspireMD, Inc., an Israel-based medical technology company established in 2005, specializes in creating and commercializing advanced medical devices. Its core expertise lies in the proprietary MicroNet stent platform technology, engineered to address various vascular and coronary diseases. The company's offerings, distributed through a network of local partners, reach markets across Europe, Latin America, the Middle East, and Asia Pacific. Key products include the CGuard carotid embolic prevention system, specifically designed for carotid artery procedures, and the MGuard Prime embolic protection systems. The MGuard Prime systems are crucial for patients experiencing acute coronary syndromes, notably acute myocardial infarction, and those undergoing saphenous vein graft coronary interventions or bypass surgery. InspireMD is also developing PVGuard, an innovative solution combining a MicroNet mesh sleeve with a self-expandable stent, aimed at peripheral vascular applications.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Insufficient data
β€”/100
Analyst data unavailable.

Latest News & Updates

News unavailable.